Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes DOI Creative Commons
Viral N. Shah,

Terry Dex,

Luigi Meneghini

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Abstract Aims In Soli‐CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin‐naive adults suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%–13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy) increased time range (TIR; primary endpoint) from 26.4% at baseline to 52.7% Week 16. This exploratory analysis examined the impact of patient‐reported satisfaction. Materials Methods Soli‐CGM was a single‐arm, 16‐week, multicentre, interventional, open‐label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) assess glycaemic metrics ( N = 124). CGM data were collected for 2‐week period before initiation iGlarLixi, after (Weeks 14–16). Treatment satisfaction assessed Diabetes Medication Satisfaction Tool (DM‐SAT, which comprises four domains: well‐being, medical control, lifestyle convenience), end‐of‐treatment. Association TIR overall (sum all items) also assessed. Results Overall, 118 (95.9%) 107 (87.0%) participants completed DM‐SAT 16, respectively. Mean score by 0.18, 0.59 (baseline) 0.78 (Week 16). A trend improvement observed domains. Improvement had positive, but weak, association (mean r 0.14). Conclusions people T2D OADs GLP‐1 RA, 16 weeks' resulted

Language: Английский

Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes DOI Creative Commons
Viral N. Shah,

Terry Dex,

Luigi Meneghini

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Abstract Aims In Soli‐CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin‐naive adults suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%–13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy) increased time range (TIR; primary endpoint) from 26.4% at baseline to 52.7% Week 16. This exploratory analysis examined the impact of patient‐reported satisfaction. Materials Methods Soli‐CGM was a single‐arm, 16‐week, multicentre, interventional, open‐label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) assess glycaemic metrics ( N = 124). CGM data were collected for 2‐week period before initiation iGlarLixi, after (Weeks 14–16). Treatment satisfaction assessed Diabetes Medication Satisfaction Tool (DM‐SAT, which comprises four domains: well‐being, medical control, lifestyle convenience), end‐of‐treatment. Association TIR overall (sum all items) also assessed. Results Overall, 118 (95.9%) 107 (87.0%) participants completed DM‐SAT 16, respectively. Mean score by 0.18, 0.59 (baseline) 0.78 (Week 16). A trend improvement observed domains. Improvement had positive, but weak, association (mean r 0.14). Conclusions people T2D OADs GLP‐1 RA, 16 weeks' resulted

Language: Английский

Citations

0